Paliperidone Palmitate Injection (PP1M)

DRUG2 trials

Sponsors

Janssen Scientific Affairs, LLC, Jiangsu Province Nanjing Brain Hospital

Conditions

Psychotic DisordersSchizophrenia

Phase 3

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

CompletedNCT02431702

Janssen Scientific Affairs, LLCPsychotic Disorders, Schizophrenia

Start: 2015-07-08End: 2019-11-12Updated: 2025-04-29

Phase 4

Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia

Not yet recruitingNCT07075237

Jiangsu Province Nanjing Brain HospitalSchizophrenia

Start: 2025-10-31End: 2027-03-31Target: 120Updated: 2025-09-29

Related Papers

Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia

The Journal of Clinical Psychiatry2023-09-212 citations

Effect of treatment with paliperidone palmitate versus oral antipsychotics on frontal lobe intracortical myelin volume in participants with recent-onset schizophrenia: Magnetic resonance imaging results from the DREaM study.

2023-03-312 citations

Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia

Journal of Managed Care & Specialty Pharmacy2023-01-241 citations

Dispersion of cognitive performance test scores on the MATRICS Consensus Cognitive Battery: A different perspective.

2022-09-051 citations

Evaluation of major treatment failure in patients with recent-onset schizophrenia or schizophreniform disorder: A post hoc analysis from the Disease Recovery Evaluation and Modification (DREaM) study

Schizophrenia Research2022-08-051 citations

The Disease Recovery Evaluation and Modification (DREaM) study: Effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorder

Schizophrenia Research2022-03-0213 citations

SU78. Intracortical Myelination Within the Frontal Lobe as a Potential Biomarker for Therapeutic Effectiveness in Antipsychotics Using MRI With Selective Myelin-Lipid Suppression at 1.5 and 3 T

Schizophrenia Bulletin2017-03-01

SA12. Baseline Demographics and Clinical Characteristics From a Prospective, Randomized, Open-Label Study of Paliperidone Palmitate Long-Acting Injection in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder

Schizophrenia Bulletin2017-03-01